Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PB 01

Next Previous
X
Search
Drug Profile

PB 01

Alternative Names: PB01

Latest Information Update: 24 Oct 2021

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator The Hudson Institute of Medical Research
  • Developer Paranta Biosciences
  • Class Carrier proteins; Glycoproteins; Recombinant proteins
  • Mechanism of Action Activin receptor antagonists; Cell differentiation modulators; Follicle stimulating hormone inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Cancer; Cystic fibrosis

Most Recent Events

  • 28 Oct 2019 No recent reports of development identified for preclinical development in Cancer in Australia (IV)
  • 28 Oct 2018 No recent reports of development identified for phase-I development in Cystic-fibrosis(In volunteers) in Australia (Inhalation)
  • 23 Nov 2016 Paranta completes a phase I trial in Healthy volunteers in Australia (ACTRN12616000496415)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top